Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma (Nature, (2022), 611, 7934, (155-160), 10.1038/s41586-022-05368-8)

Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos Torres-Cabala, Isabella C. Glitza, Fei Duan, Denái R. Milton, Klaus Busam, Lauren Simpson, Jennifer L. McQuade, Michael K. Wong, Jeffrey E. Gershenwald, Jeffrey E. Lee, Ryan P. Goepfert, Emily Z. Keung, Sarah B. Fisher, Allison Betof-Warner, Alexander N. ShoushtariMargaret Callahan, Daniel Coit, Edmund K. Bartlett, Danielle Bello, Parisa Momtaz, Courtney Nicholas, Aidi Gu, Xuejun Zhang, Brinda Rao Korivi, Madhavi Patnana, Sapna P. Patel, Adi Diab, Anthony Lucci, Victor G. Prieto, Michael A. Davies, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Charlotte Ariyan, Hussein A. Tawbi

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

In the version of this article initially published, the surname of author Michael T. Tetzlaff was misspelled as ‘Tezlaff.’ In addition, the Acknowledgements section omitted mention of grant P50CA221703 from the National Cancer Institute of the National Institutes of Health, which supported the work. The errors have been corrected in the HTML and PDF versions of the article.

Original languageEnglish (US)
Pages (from-to)E23
JournalNature
Volume615
Issue number7953
DOIs
StatePublished - Mar 23 2023

ASJC Scopus subject areas

  • General

MD Anderson CCSG core facilities

  • Biostatistics Resource Group

Fingerprint

Dive into the research topics of 'Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma (Nature, (2022), 611, 7934, (155-160), 10.1038/s41586-022-05368-8)'. Together they form a unique fingerprint.

Cite this